Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies
about
My approach to the treatment of sclerodermaTomography patterns of lung disease in systemic sclerosisN-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control studyPoor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fractionConnective tissue disease-associated pulmonary arterial hypertension.Diagnosis and treatment of connective tissue disease-associated interstitial lung disease.Pulmonary hypertension in Saudi Arabia: A single center experience.Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension.Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era.Treatment of pulmonary arterial hypertension in connective tissue disease.Performance of screening algorithms in systemic sclerosis-related pulmonary arterial hypertension: a systematic review.Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension.Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis.Frequencies of borderline pulmonary hypertension before and after the DETECT algorithm: results from a prospective systemic sclerosis cohort.Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review.Disease-related autoantibody profile in patients with systemic sclerosis.Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg.Outcome of patients with severe PH due to lung disease with and without targeted therapy.Ultrasound signs of pulmonary fibrosis in systemic sclerosis as timely indicators for chest computed tomography.Pulmonary Arterial Hypertension: Combination Therapy in Practice.Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis.Systemic sclerosis-associated pulmonary arterial hypertension.
P2860
Q24618843-CFBE33E3-3245-4732-A6B7-2DFEB8339D97Q28072188-A082607E-5CE3-4E9E-AF94-37CC143F846EQ30463476-48943343-5D3D-4605-8B8C-6670B3DB137DQ33788474-0B11CF74-B52F-4CB7-85ED-164C4D1D6625Q35029607-A8ED0B58-98A2-4D83-9B0F-CE54AAD4DEFFQ36664408-D17EEE39-49AF-45A3-B47A-4114BB385266Q36886438-29679B94-75DD-4D35-913C-41A78BF1024BQ37274520-8E3D41F5-40DE-4636-8D1B-87EF46006C9EQ37345940-AD482830-DAF4-4969-914D-A51DEB672568Q38012530-36BCADB8-8FEF-4B68-9062-7A12AF968C1DQ38101137-784BB507-51F2-4285-9BDC-20D0B4533E98Q38112387-ED63AAB1-9810-436D-9AA4-41DD6DC650DEQ38204351-87B5885C-7CD9-4D02-9939-0F09E4F8F9A3Q38367248-83BF6908-372A-45C5-A24A-B96EEBDA27F4Q38525952-57EAE656-70E4-4E9F-9FFD-C8893DE0805AQ38721897-18441CCB-88D9-4049-8809-BCF7FB66DA8BQ40814361-8F2FB668-A770-49CB-844B-766524ADB423Q43184339-24C7B964-0E5E-46E0-93C0-16319C63F026Q46109875-CCDECF6C-7D0D-4AAC-907B-81EAF9178AD5Q47194067-F0B125F0-9614-45AB-A36E-7002720DAE37Q47372819-AAC4F53D-22F3-4662-93EC-627F7795AA32Q47685250-F93227D3-8AEC-4F0B-B1BA-956D2A8DEA5EQ50098235-98024020-7696-4288-B60B-0F6EEEDD6E07Q51135443-6D04BB50-CC4F-4E29-B86C-08F9CB40BC0BQ51619263-231946F8-1132-44CE-9032-142C6ADF9BB2Q52364945-9636080E-048C-4170-9268-EEB6406368D6Q54957551-298A202F-261F-4F4D-945B-66992B8141B9Q55309547-86056700-AA50-4B99-9437-D7EC378D6391
P2860
Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies
description
scientific article published on 01 August 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2011
@uk
name
Systemic sclerosis-related pul ...... rterial hypertension therapies
@en
Systemic sclerosis-related pul ...... rterial hypertension therapies
@nl
type
label
Systemic sclerosis-related pul ...... rterial hypertension therapies
@en
Systemic sclerosis-related pul ...... rterial hypertension therapies
@nl
prefLabel
Systemic sclerosis-related pul ...... rterial hypertension therapies
@en
Systemic sclerosis-related pul ...... rterial hypertension therapies
@nl
P2093
P2860
P50
P356
P1476
Systemic sclerosis-related pul ...... rterial hypertension therapies
@en
P2093
Ari Zaiman
Gérald Simonneau
Noah Lechtzin
Paul M Hassoun
Reda E Girgis
Stephen C Mathai
P2860
P304
P356
10.1002/ART.30423
P577
2011-08-01T00:00:00Z